scholarly article | Q13442814 |
P50 | author | Dimitrios Spandidos | Q18701325 |
Katerina D Samara | Q79712629 | ||
P2093 | author name string | Katerina M Antoniou | |
George A Margaritopoulos | |||
Giannoula Soufla | |||
Nikolaos M Siafakas | |||
Dimitra Kappou | |||
Emmanouil Symvoulakis | |||
Evi Vassalou | |||
Rena Lymbouridou | |||
P2860 | cites work | ??? | Q28215495 |
Survival of cancer cells is maintained by EGFR independent of its kinase activity | Q24309274 | ||
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
Mutations of the BRAF gene in human cancer | Q27860760 | ||
MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis | Q28217248 | ||
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo | Q28240836 | ||
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis | Q28260133 | ||
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis | Q28278590 | ||
The biochemistry of apoptosis | Q29547741 | ||
Lung cancer in never smokers--a different disease | Q29615414 | ||
Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease | Q30442380 | ||
Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. | Q34333813 | ||
The epidemiology of interstitial lung disease and its association with lung cancer | Q35875981 | ||
The prognosis of cryptogenic fibrosing alveolitis | Q36442446 | ||
Cryptogenic fibrosing alveolitis and lung cancer | Q36463491 | ||
Evolving concepts of apoptosis in idiopathic pulmonary fibrosis | Q36493966 | ||
Techniques used in studies of age-related DNA methylation changes | Q36521045 | ||
A translational view of the molecular pathogenesis of lung cancer | Q36780534 | ||
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis | Q36951842 | ||
RAS: target for cancer therapy | Q37271795 | ||
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Q37376100 | ||
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis | Q37591872 | ||
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. | Q40184040 | ||
Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases | Q40431691 | ||
Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis | Q42810857 | ||
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results | Q43223134 | ||
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis | Q47680928 | ||
Down-regulation of K-ras and H-ras in human brain gliomas. | Q48779053 | ||
Lung cancer associated with usual interstitial pneumonia. | Q51009716 | ||
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. | Q52927020 | ||
Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. | Q54446707 | ||
P433 | issue | 4 | |
P921 | main subject | pulmonary fibrosis | Q32446 |
idiopathic pulmonary fibrosis | Q2290446 | ||
P304 | page(s) | 262-269 | |
P577 | publication date | 2010-08-01 | |
P1433 | published in | Journal of Receptors and Signal Transduction | Q6295837 |
P1476 | title | Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF) | |
P478 | volume | 30 |
Q92624635 | A network-based pathway-extending approach using DNA methylation and gene expression data to identify altered pathways |
Q37421028 | Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway |
Q58129865 | Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis |
Q54231908 | Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. |
Q37341340 | Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer. |
Q42282467 | Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score |
Q38187149 | Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. |
Q47651544 | Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts |
Q35830712 | Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis |
Q37707603 | Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis |
Q41617768 | Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-β1 mediated Smad2/3 and ERK1/2 activation |
Q56243543 | Lung cancer and interstitial lung disease: a literature review |
Q35889180 | MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation |
Q92564621 | TGFβ1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjögren's syndrome |
Q39114742 | Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells |
Q36480367 | p70 ribosomal S6 kinase regulates subpleural fibrosis following transforming growth factor-α expression in the lung |
Search more.